BASINGSTOKE, England and PHILADELPHIA, Pennsylvania, February 14 /PRNewswire-FirstCall/ -- Shire plc will announce full year 2006 earnings on Friday 23 February 2007.
Results press release will be issued at: 12:00 GMT / 07:00 ET
Investor Meeting & conference call time: 14:00 GMT / 09:00 ET
Live analyst presentation and conference call:
Matthew Emmens, Chief Executive Officer and Angus Russell, Chief Financial Officer will host the investor and analyst meeting and live conference call at 14:00 GMT/9:00 ET. The venue for the meeting will be at the offices of Financial Dynamics, Holborn Gate, 26 Southampton Buildings, London WC2A 1PB
Please RSVP claire.rowell@fd.com for the live presentation. Live conference call and Webcast: The details of the live conference call and webcast are as follows: US Toll Free Dial In Number: 1-866-793-4279 UK Toll Free Dial In Number: 0800-358-2705 Standard International Dial In Number: +44-(0)-20-8609-0205 Conference ID / Pin Code: 292846# Audio webcast: www.shire.com, in the Investor Relations/Events section Please RSVP ssalah@shire.com for the conference call Replay:
A replay of the presentation will be available for two weeks. Details are as follows:
UK Dial In Number: 0800-358-2189 USA Toll Free Number: 1-866-676-5865 Std International Number: +44-(0)-20-8609-0289 Replay Access Number: 163318# Webcast Replay: www.shire.com, in the Investor Relations/Events section Notes to editors SHIRE PLC
Shire’s strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.
Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.
For further information on Shire, please visit the Company’s website: www.shire.com.
Shire PLC
CONTACT: For further information please contact: Investor Relations,Souheil Salah (Rest of the World): +44-1256-894-160, Heidi Wunder (NorthAmerica): +1-484-595-8970
